SK8198A3 - Hormone patch - Google Patents

Hormone patch Download PDF

Info

Publication number: SK8198A3
Authority: SK; Slovakia
Prior art keywords: therapeutic system; transdermal therapeutic; ethoxyethoxy; ethanol; oleic acid
Prior art date: 1995-07-22

Application number

SK81-98A

Other languages

English (en)

Slovak (sk)

Inventor

Gunter Cordes

Martin Siegmund

Original Assignee

Gruenenthal Chemie

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-07-22

Filing date

1996-07-22

Publication date

1998-06-03

1996-07-22 Application filed by Gruenenthal Chemie filed Critical Gruenenthal Chemie

1998-06-03 Publication of SK8198A3 publication Critical patent/SK8198A3/sk

Links

229940088597 hormone Drugs 0.000 title claims description 9
239000005556 hormone Substances 0.000 title claims description 9
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims abstract description 26
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims abstract description 26
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims abstract description 26
239000005642 Oleic acid Substances 0.000 claims abstract description 26
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims abstract description 26
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims abstract description 26
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims abstract description 26
XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims abstract description 23
230000001225 therapeutic effect Effects 0.000 claims abstract description 19
239000000126 substance Substances 0.000 claims abstract description 15
239000000853 adhesive Substances 0.000 claims abstract description 11
230000001070 adhesive effect Effects 0.000 claims abstract description 11
239000003098 androgen Substances 0.000 claims abstract description 6
239000000262 estrogen Substances 0.000 claims abstract description 6
239000000583 progesterone congener Substances 0.000 claims abstract description 6
NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims abstract description 3
239000000203 mixture Substances 0.000 claims description 19
239000010408 film Substances 0.000 claims description 15
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 14
229930182833 estradiol Natural products 0.000 claims description 14
229960005309 estradiol Drugs 0.000 claims description 12
IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 claims description 11
229960001652 norethindrone acetate Drugs 0.000 claims description 11
WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 claims description 10
229960004400 levonorgestrel Drugs 0.000 claims description 10
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 7
BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 claims description 6
NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 6
229940011871 estrogen Drugs 0.000 claims description 5
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 4
BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 claims description 4
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 4
229960002568 ethinylestradiol Drugs 0.000 claims description 4
229960003604 testosterone Drugs 0.000 claims description 4
GOXQRTZXKQZDDN-UHFFFAOYSA-N 2-Ethylhexyl acrylate Chemical compound CCCCC(CC)COC(=O)C=C GOXQRTZXKQZDDN-UHFFFAOYSA-N 0.000 claims description 3
CQEYYJKEWSMYFG-UHFFFAOYSA-N butyl acrylate Chemical compound CCCCOC(=O)C=C CQEYYJKEWSMYFG-UHFFFAOYSA-N 0.000 claims description 3
238000010526 radical polymerization reaction Methods 0.000 claims description 3
SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims description 2
OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 claims description 2
XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 claims description 2
239000013039 cover film Substances 0.000 claims description 2
150000002148 esters Chemical class 0.000 claims description 2
229960003575 estradiol acetate Drugs 0.000 claims description 2
239000000178 monomer Substances 0.000 claims description 2
239000000186 progesterone Substances 0.000 claims description 2
229960003387 progesterone Drugs 0.000 claims description 2
150000003839 salts Chemical class 0.000 claims description 2
239000000546 pharmaceutical excipient Substances 0.000 claims 2
BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 claims 1
239000003431 cross linking reagent Substances 0.000 claims 1
239000003814 drug Substances 0.000 abstract description 5
229940079593 drug Drugs 0.000 abstract description 3
ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 14
239000003623 enhancer Substances 0.000 description 6
239000007787 solid Substances 0.000 description 6
238000000034 method Methods 0.000 description 5
210000000434 stratum corneum Anatomy 0.000 description 5
OIQOAYVCKAHSEJ-UHFFFAOYSA-N 2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol;hexadecanoic acid;octadecanoic acid Chemical compound OCCOCC(OCCO)COCCO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O OIQOAYVCKAHSEJ-UHFFFAOYSA-N 0.000 description 4
239000011521 glass Substances 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
230000035515 penetration Effects 0.000 description 4
210000003491 skin Anatomy 0.000 description 4
238000003756 stirring Methods 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
239000013543 active substance Substances 0.000 description 3
239000011248 coating agent Substances 0.000 description 3
238000000576 coating method Methods 0.000 description 3
230000000052 comparative effect Effects 0.000 description 3
238000001035 drying Methods 0.000 description 3
230000000694 effects Effects 0.000 description 3
-1 ethoxyethoxy Chemical group 0.000 description 3
239000011888 foil Substances 0.000 description 3
238000009472 formulation Methods 0.000 description 3
239000000463 material Substances 0.000 description 3
RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
239000002253 acid Substances 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
229940030486 androgens Drugs 0.000 description 2
229920001577 copolymer Polymers 0.000 description 2
125000005456 glyceride group Chemical group 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
229920006267 polyester film Polymers 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
230000001681 protective effect Effects 0.000 description 2
230000002110 toxicologic effect Effects 0.000 description 2
231100000027 toxicology Toxicity 0.000 description 2
ARIWANIATODDMH-AWEZNQCLSA-N 1-lauroyl-sn-glycerol Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)CO ARIWANIATODDMH-AWEZNQCLSA-N 0.000 description 1
LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
QMBJSIBWORFWQT-DFXBJWIESA-N Chlormadinone acetate Chemical compound C1=C(Cl)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 QMBJSIBWORFWQT-DFXBJWIESA-N 0.000 description 1
ARIWANIATODDMH-UHFFFAOYSA-N Lauric acid monoglyceride Natural products CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000012790 adhesive layer Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
229960001616 chlormadinone acetate Drugs 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
239000008240 homogeneous mixture Substances 0.000 description 1
230000037368 penetrate the skin Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000013557 residual solvent Substances 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
239000002904 solvent Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
230000001839 systemic circulation Effects 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000013271 transdermal drug delivery Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Oil, Petroleum & Natural Gas (AREA)
Dermatology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Power Steering Mechanism (AREA)
Surgical Instruments (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Steroid Compounds (AREA)

SK81-98A 1995-07-22 1996-07-22 Hormone patch SK8198A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE19526864A DE19526864A1 (de)	1995-07-22	1995-07-22	Hormonpflaster
PCT/EP1996/003229 WO1997003698A1 (de)	1995-07-22	1996-07-22	Hormonpflaster

Publications (1)

Publication Number	Publication Date
SK8198A3 true SK8198A3 (en)	1998-06-03

Family

ID=7767564

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK81-98A SK8198A3 (en)	1995-07-22	1996-07-22	Hormone patch

Country Status (21)

Country	Link
US (1)	US5985311A (cs)
EP (1)	EP0840621B1 (cs)
JP (1)	JPH11504038A (cs)
KR (1)	KR19990035795A (cs)
CN (1)	CN1195994A (cs)
AT (1)	ATE212234T1 (cs)
AU (1)	AU6786696A (cs)
BR (1)	BR9609794A (cs)
CA (1)	CA2227538A1 (cs)
CZ (1)	CZ20498A3 (cs)
DE (3)	DE19526864A1 (cs)
DK (1)	DK0840621T3 (cs)
ES (1)	ES2171710T3 (cs)
HU (1)	HUP9900301A3 (cs)
MX (1)	MX9800469A (cs)
NO (1)	NO980277L (cs)
NZ (1)	NZ316026A (cs)
PL (1)	PL324552A1 (cs)
PT (1)	PT840621E (cs)
SK (1)	SK8198A3 (cs)
WO (1)	WO1997003698A1 (cs)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20050276836A1 (en) *	1997-06-11	2005-12-15	Michelle Wilson	Coated vaginal devices for vaginal delivery of therapeutically effective and/or health-promoting agents
DE19728516C2 (de) *	1997-07-04	1999-11-11	Sanol Arznei Schwarz Gmbh	TTS zur Verabreichung von Levonorgestrel und gegebenenfalls Estradiol
FR2779062A1 (fr) *	1998-06-02	1999-12-03	Investigations Therapeutiques	Preparation sous forme galenique simple visant a limiter les effets induits durant la menopause et posterieurement et traitement avec cette preparation
DE19901085C2 (de) *	1999-01-14	2003-12-18	Lohmann Therapie Syst Lts	Transdermales therapeutisches System mit einer selbstklebenden Matrix, enthaltend organische Säure-Additionssalze von Alkaloiden des Morphin- bzw. Morphinantyps
USRE44145E1 (en)	2000-07-07	2013-04-09	A.V. Topchiev Institute Of Petrochemical Synthesis	Preparation of hydrophilic pressure sensitive adhesives having optimized adhesive properties
EP1216699A1 (de) *	2000-12-21	2002-06-26	Schering Aktiengesellschaft	Transdermalsystem enthaltend ein hochpotentes Gestagen
US8541021B2 (en)	2001-05-01	2013-09-24	A.V. Topchiev Institute Of Petrochemical Synthesis	Hydrogel compositions demonstrating phase separation on contact with aqueous media
US8206738B2 (en)	2001-05-01	2012-06-26	Corium International, Inc.	Hydrogel compositions with an erodible backing member
US8840918B2 (en)	2001-05-01	2014-09-23	A. V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences	Hydrogel compositions for tooth whitening
EP1390084B1 (en)	2001-05-01	2011-03-23	A.V. Topchiev Institute of Petrochemical Synthesis	Two-phase, water-absorbent bioadhesive composition
US20050113510A1 (en)	2001-05-01	2005-05-26	Feldstein Mikhail M.	Method of preparing polymeric adhesive compositions utilizing the mechanism of interaction between the polymer components
US20050215727A1 (en)	2001-05-01	2005-09-29	Corium	Water-absorbent adhesive compositions and associated methods of manufacture and use
ES2331302T3 (es)	2001-05-01	2009-12-29	A.V. Topchiev Institute Of Petrochemical Synthesis	Composiciones de hidrogel.
KR20030028253A (ko) *	2001-09-27	2003-04-08	(주)지씨아이	잔탄검과 알긴을 이용한 항고지단백혈증 경피투과제제의제조
JP4919573B2 (ja) *	2002-08-09	2012-04-18	帝國製薬株式会社	ノルエチステロン含有外用貼付剤
EP1547600B1 (en)	2002-08-09	2013-02-13	Teikoku Seiyaku Co., Ltd.	Estradiol-containing patch
JP5027373B2 (ja) *	2002-08-09	2012-09-19	帝國製薬株式会社	エストラジオール含有貼付剤
KR20040037653A (ko) *	2002-10-29	2004-05-07	대한민국(경북대학교 총장)	갈변 방지제
JO2492B1 (en)	2003-04-28	2009-10-05	شيرينج ايه جي	A pharmaceutical formula in the form of aqueous gel for the skin use of its active ingredients
RU2380092C2 (ru)	2004-01-30	2010-01-27	Кориум Интернэшнл, Инк.	Быстро растворяющаяся пленка для доставки активного агента
EP1791575B1 (en)	2004-08-05	2014-10-08	Corium International, Inc.	Adhesive composition
WO2006036899A2 (en) *	2004-09-27	2006-04-06	Corium International, Inc.	Transdermal systems for the delivery of estrogens and progestins
WO2006051818A1 (ja) *	2004-11-10	2006-05-18	Hisamitsu Pharmaceutical Co., Inc.	外用製剤及び貼付剤
EP1806151B1 (en) *	2004-11-10	2012-05-23	Hisamitsu Pharmaceutical Co., Inc.	Drug for external use and adhesive patch
US8263680B2 (en) *	2005-09-23	2012-09-11	Henkel Ag & Co. Kgaa	Acrylic polymer-based adhesives
WO2007056105A2 (en)	2005-11-02	2007-05-18	Transpharma Medical Ltd.	Human growth hormone patch formulations
WO2008091588A1 (en)	2007-01-22	2008-07-31	Targacept, Inc.	Intranasal, buccal, and sublingual administration of metanicotine analogs
JP5358574B2 (ja) *	2007-08-17	2013-12-04	アルションセラピューティクス，インコーポレイテッド	高濃度の局所麻酔薬調合物
US8119694B2 (en)	2008-08-15	2012-02-21	Arcion Therapeutics, Inc.	High concentration local anesthetic formulations
DE102008059054A1 (de)	2008-11-26	2010-05-27	Otto Bock Pur Life Science Gmbh	Polyurethanpflaster für die transdermale Applikation von Wirkstoffen und Verfahren zu dessen Herstellung
WO2010083035A2 (en)	2009-01-14	2010-07-22	Corium International, Inc.	Transdermal administration of tamsulosin
US9301920B2 (en)	2012-06-18	2016-04-05	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
US8633178B2 (en)	2011-11-23	2014-01-21	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
US10806740B2 (en)	2012-06-18	2020-10-20	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
US20130338122A1 (en)	2012-06-18	2013-12-19	Therapeuticsmd, Inc.	Transdermal hormone replacement therapies
US20150196640A1 (en)	2012-06-18	2015-07-16	Therapeuticsmd, Inc.	Progesterone formulations having a desirable pk profile
US10806697B2 (en)	2012-12-21	2020-10-20	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en)	2012-12-21	2019-11-12	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en)	2012-12-21	2022-02-15	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en)	2012-12-21	2020-02-25	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en)	2012-12-21	2022-03-08	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en)	2012-12-21	2020-01-21	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en)	2012-12-21	2015-11-10	Therapeuticsmd, Inc.	Soluble estradiol capsule for vaginal insertion
EP3145489A1 (en)	2014-05-22	2017-03-29	TherapeuticsMD, Inc.	Natural combination hormone replacement formulations and therapies
RS62007B1 (sr)	2014-06-06	2021-07-30	Ovid Therapeutics Inc	Postupci pojačavanja tonične inhibicije i lečenja angelmanovog sindroma
RU2016141135A (ru)	2014-07-29	2018-08-28	Терапьютиксмд, Инк.	Трансдермальный крем
EP4541420A3 (en)	2015-07-17	2025-06-25	Ovid Therapeutics Inc.	Methods of treating developmental disorders with gaboxadol
US9682069B2 (en)	2015-07-17	2017-06-20	Ovid Therapeutics Inc	Methods of treating Dravet syndrome
US10328087B2 (en)	2015-07-23	2019-06-25	Therapeuticsmd, Inc.	Formulations for solubilizing hormones
WO2017173044A1 (en)	2016-04-01	2017-10-05	Therapeuticsmd Inc.	Steroid hormone compositions in medium chain oils
WO2017173071A1 (en)	2016-04-01	2017-10-05	Therapeuticsmd, Inc.	Steroid hormone pharmaceutical composition
US10660967B2 (en)	2016-10-21	2020-05-26	Augusta University Research Institute, Inc.	Curcumin conjugates and methods of use thereof
US10071083B2 (en)	2017-02-03	2018-09-11	Ovid Therapeutics Inc	Use of gaboxadol in the treatment of tinnitus
EP3713644B1 (en)	2017-11-20	2024-08-07	University of Georgia Research Foundation, Inc.	Compositions and methods for modulating hif-2a to improve muscle generation and repair
US20210137960A1 (en)	2018-02-01	2021-05-13	Yale University	Compositions and methods for inhibition of nuclear-penetrating antibodies
WO2021077070A1 (en)	2019-10-18	2021-04-22	Yale University	Compositions and methods for inhibition of cell-penetrating antibodies
US11633405B2 (en)	2020-02-07	2023-04-25	Therapeuticsmd, Inc.	Steroid hormone pharmaceutical formulations
US11850220B2 (en)	2020-05-19	2023-12-26	Augusta University Research Institute, Inc.	Synthesis of ibuprofen hybrid conjugates as anti-inflammatory and analgesic agents
WO2022146994A1 (en)	2020-12-28	2022-07-07	Georgia Tech Research Corporation	Glycosylated histone deacetylase inhibitors and methods of making and using the same
US11858908B2 (en)	2021-01-19	2024-01-02	Augusta University Research Institute, Inc.	Compositions and methods for inhibiting IDO1
US12303503B1 (en)	2023-11-16	2025-05-20	Biobina Llc	Use of dextromethorphan in combination with CYP2D6 and CYP3A4 enzyme inhibitors for the treatment of pain
WO2025264860A2 (en)	2024-06-18	2025-12-26	Yale University	Methods of treating post-covid airway disease

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5296230A (en) *	1985-02-25	1994-03-22	Rutgers, The State University Of New Jersey	Transdermal fertility control system and process
CH674618A5 (cs) *	1987-04-02	1990-06-29	Ciba Geigy Ag
US5223261A (en) *	1988-02-26	1993-06-29	Riker Laboratories, Inc.	Transdermal estradiol delivery system
DE3910578A1 (de) *	1989-03-29	1990-10-04	Schering Ag	Mittel zur transdermalen applikation enthaltend gestoden
EP0371469B1 (en) *	1988-11-30	1995-02-08	Toyota Jidosha Kabushiki Kaisha	Apparatus for driving piezoelectric element for closing and opening valve member
CA2004203A1 (en) *	1988-12-01	1990-06-01	Sharad K. Govil	Compositions for transdermal delivery of estradiol
US5053227A (en) *	1989-03-22	1991-10-01	Cygnus Therapeutic Systems	Skin permeation enhancer compositions, and methods and transdermal systems associated therewith
EP0399432B1 (en) *	1989-05-25	1994-06-22	Takeda Chemical Industries, Ltd.	Transdermal therapeutic composition
CA2065311C (en) *	1989-09-08	2000-01-11	Chia-Ming Chiang	Solid matrix system for transdermal drug delivery
DE3933460A1 (de) *	1989-10-06	1991-04-18	Lohmann Therapie Syst Lts	Oestrogenhaltiges wirkstoffpflaster
DE3942232A1 (de) *	1989-12-21	1991-06-27	Beiersdorf Ag	Schmelzhaftkleber auf acrylatbasis
DE4020144A1 (de) *	1990-06-25	1992-01-09	Lohmann Therapie Syst Lts	Pflaster mit hohem gehalt an weichmachenden inhaltsstoffen
DE4210165A1 (de) *	1991-07-30	1993-02-04	Schering Ag	Transdermale therapeutische systeme
US5518734A (en) *	1991-09-25	1996-05-21	Beta Pharmaceuticals Co.	Transdermal delivery system for estradiol and process for manufacturing said device
US5676968A (en) *	1991-10-31	1997-10-14	Schering Aktiengesellschaft	Transdermal therapeutic systems with crystallization inhibitors
DE4210711A1 (de) *	1991-10-31	1993-05-06	Schering Ag Berlin Und Bergkamen, 1000 Berlin, De	Transdermale therapeutische systeme mit kristallisationsinhibitoren
IT1253265B (it) *	1991-11-25	1995-07-14	Rotta Research Lab	Preparato a matrice copolimerica adesiva a base acrilica per il rilascio transdermico dell'estradiolo.
US5314685A (en) *	1992-05-11	1994-05-24	Agouron Pharmaceuticals, Inc.	Anhydrous formulations for administering lipophilic agents
GB2273044B (en) *	1992-12-02	1997-04-09	Pacific Chem Co Ltd	Medicinal patches for percutaneous administration
DE4240806A1 (de) *	1992-12-01	1994-06-09	Schering Ag	Mittel zur transdermalen Applikation enthaltend 14alpha,17alpha-Ethanoestra-1,3,5(10)-trien-3,17beta-diol
ES2160623T3 (es) *	1992-12-31	2001-11-16	Sunkyong Ind Ltd	Composiciones farmaceuticas mejoradas para la penetracion en la piel de piroxicam.
DE4309830C1 (de) *	1993-03-26	1994-05-05	Lohmann Therapie Syst Lts	Wirkstoffpflaster für die Abgabe von Estradiol an die Haut
US5385736A (en) *	1993-07-12	1995-01-31	Minnesota Mining And Manufacturing Company	Transdermal melatonin delivery system
AU7517794A (en) *	1993-08-16	1995-03-14	Cygnus Therapeutic Systems	Transdermal delivery system using a combination of permeation enhancers
DE4333595A1 (de) *	1993-10-01	1995-04-06	Labtec Gmbh	Transdermales therapeutisches System zur Applikation von Arzneimitteln auf die Haut
WO1995020392A1 (de) *	1994-01-27	1995-08-03	Schering Aktiengesellschaft	MITTEL ZUR TRANSDERMALEN APPLIKATION ENTHALTEND 14α,17α-ETHANOESTRA-1,3,5(10)-TRIEN-3,17β-DIOL
CA2198390C (en) *	1994-09-14	2009-08-11	James E. Garbe	Matrix for transdermal drug delivery
WO1996008255A1 (en) *	1994-09-14	1996-03-21	Minnesota Mining And Manufacturing Company	Transdermal device for delivery of levonorgestrel

1995
- 1995-07-22 DE DE19526864A patent/DE19526864A1/de not_active Withdrawn
1996
- 1996-07-22 PL PL96324552A patent/PL324552A1/xx unknown
- 1996-07-22 EP EP96928368A patent/EP0840621B1/de not_active Expired - Lifetime
- 1996-07-22 ES ES96928368T patent/ES2171710T3/es not_active Expired - Lifetime
- 1996-07-22 BR BR9609794A patent/BR9609794A/pt active Search and Examination
- 1996-07-22 DE DE59608650T patent/DE59608650D1/de not_active Expired - Fee Related
- 1996-07-22 CZ CZ98204A patent/CZ20498A3/cs unknown
- 1996-07-22 PT PT96928368T patent/PT840621E/pt unknown
- 1996-07-22 NZ NZ316026A patent/NZ316026A/xx unknown
- 1996-07-22 DK DK96928368T patent/DK0840621T3/da active
- 1996-07-22 WO PCT/EP1996/003229 patent/WO1997003698A1/de not_active Ceased
- 1996-07-22 DE DE19680582T patent/DE19680582D2/de not_active Expired - Fee Related
- 1996-07-22 AU AU67866/96A patent/AU6786696A/en not_active Abandoned
- 1996-07-22 AT AT96928368T patent/ATE212234T1/de not_active IP Right Cessation
- 1996-07-22 JP JP9506320A patent/JPH11504038A/ja not_active Ceased
- 1996-07-22 SK SK81-98A patent/SK8198A3/sk unknown
- 1996-07-22 CN CN96196894A patent/CN1195994A/zh active Pending
- 1996-07-22 HU HU9900301A patent/HUP9900301A3/hu unknown
- 1996-07-22 KR KR1019980700454A patent/KR19990035795A/ko not_active Withdrawn
- 1996-07-22 CA CA002227538A patent/CA2227538A1/en not_active Abandoned
1998
- 1998-01-15 MX MX9800469A patent/MX9800469A/es not_active IP Right Cessation
- 1998-01-21 NO NO980277A patent/NO980277L/no unknown
- 1998-01-22 US US09/010,534 patent/US5985311A/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
KR19990035795A (ko)	1999-05-25
PL324552A1 (en)	1998-06-08
DK0840621T3 (cs)	2002-04-15
BR9609794A (pt)	1999-03-16
PT840621E (pt)	2002-06-28
HUP9900301A2 (hu)	1999-06-28
CN1195994A (zh)	1998-10-14
MX9800469A (es)	1998-09-30
DE19680582D2 (de)	1998-10-29
EP0840621B1 (de)	2002-01-23
ATE212234T1 (de)	2002-02-15
DE59608650D1 (de)	2002-03-14
JPH11504038A (ja)	1999-04-06
DE19526864A1 (de)	1997-01-23
NZ316026A (en)	1999-08-30
ES2171710T3 (es)	2002-09-16
CA2227538A1 (en)	1997-02-06
CZ20498A3 (cs)	1998-06-17
US5985311A (en)	1999-11-16
WO1997003698A1 (de)	1997-02-06
NO980277D0 (no)	1998-01-21
EP0840621A1 (de)	1998-05-13
AU6786696A (en)	1997-02-18
HUP9900301A3 (en)	1999-11-29
NO980277L (no)	1998-01-21

Publication	Publication Date	Title
SK8198A3 (en)	1998-06-03	Hormone patch
RU2154455C2 (ru)	2000-08-20	Чрескожные терапевтические системы, содержащие половые стероиды
US5725874A (en)	1998-03-10	Solubilizer and external preparations containing the same
AU735944B2 (en)	2001-07-19	Transdermal device for the delivery of testosterone
US6010716A (en)	2000-01-04	Pharmaceutical composition for transdermal administration
US5788983A (en)	1998-08-04	Transdermal controlled delivery of pharmaceuticals at variable dosage rates and processes
RU2110261C1 (ru)	1998-05-10	Система трансдермальной доставки
PL178896B1 (pl)	2000-06-30	Samoprzylepny przezskórny układ matrycowy do podawania estrogenu i/lub progestagenu w sposób nie naruszający skóry oraz sposoby jego wytwarzania
JP2002518434A (ja)	2002-06-25	ステロイドホルモンを高速度で輸送するマトリックス型経皮薬物輸送システムとホルモン代償療法へのこの種のシステムの使用
MXPA94003365A (es)	2005-03-09	Sistema terapeutico transdermico conteniendo estradiol.
JPH0372416A (ja)	1991-03-27	経皮用製剤
SK51595A3 (en)	1997-03-05	Plaster for the transdermal administration of volatile, pharmaceutically active, chemically alkaline active ingredients, and processs for producing the same
SK40698A3 (en)	1998-09-09	Transdermal matrix system
EP0773028A1 (en)	1997-05-14	Percutaneously absorbable preparation
JP2003530354A (ja)	2003-10-14	経皮製剤において高親油性有効成分の透過促進剤として利用するための組成物
CN101843603B (zh)	2012-06-27	无需渗透促进剂的激素透皮传递
SK278438B6 (en)	1997-05-07	The composition for transdermal application with gestodene content
AU2004298930B2 (en)	2009-11-26	Transdermal delivery system of hormones without penetration enhancers
JPH09508911A (ja)	1997-09-09	デソゲストレルを含有する経皮適用剤
PL187275B1 (pl)	2004-06-30	Preparat farmaceutyczny, zwłaszcza transdermalny system terapeutyczny, zawierający 17-beta-estradiol oraz sposób wytwarzania tego preparatu farmaceutycznego
JPH07101852A (ja)	1995-04-18	経皮吸収貼付剤
HK1074801B (en)	2010-05-20	Transdermal delivery system of gestodene